All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Experts Expand on the Impact of Removing REMS Requirements for CAR T-Cell Access in Hematologic Malignancies

August 21st 2025

Three experts discuss the implications of the FDA's removal of REMS requirements for CAR T-cell therapy in hematologic malignancies in the following video.

Alice T. Shaw named Chair of Department of Medical Oncology at Dana-Farber Cancer Institute

August 21st 2025

Alice T. Shaw, MD, PhD, has been named Chair of the Department of Medical Oncology at Dana-Farber Cancer Institute.

European Commission Approves Zanubrutinib Tablet Formulation for All Indications in B-Cell Malignancies

August 21st 2025

The European approval of a zanubrutinb tablet formulation covers indications in CLL, Waldenström macroglobulinemia, MZL, and follicular lymphoma.

Alpha1H Demonstrates Clinical Benefit in NMIBC

August 21st 2025

Alpha1H met all primary and secondary end points in a phase 2 study in non–muscle-invasive bladder cancer.

SCLC Data Drive Changes in First-Line Maintenance and Second-Line Care

August 21st 2025

Five experts gathered for the OncLive Peer Exchange to discuss SCLC data that continues to drive the evolving treatment paradigm.

AI Is Already Aiding Clinical Practice Across the Cancer Care Continuum

August 21st 2025

Clinicians spanning a spectrum of cancer subtypes discuss how they are currently using artificial intelligence in their daily practice.

Considerations for Selection and Sequencing in Polycythemia Vera and Myelofibrosis

August 21st 2025

Naseema Gangat, MBBS, delves into the role of ruxolitinib as a standard of care for the treatment of patients with polycythemia vera and myelofibrosis.

Fruquintinib Efficacy Data Support Its Use in the Third-Line Advanced CRC Setting

August 20th 2025

John Marshall, MD, discusses fruquintinib’s efficacy in later-line CRC, advocating for the agent’s use as maintenance therapy to avoid overtreatment.

Darolutamide Doublet Is Redefining Treatment Decision-Making for mCSPC

August 20th 2025

Matthew R. Smith, MD, PhD, discusses findings from the ARANOTE trial that confirm the efficacy of darolutamide plus ADT in mCSPC.

Leaders Drive Theranostics Expansion to Transform Cancer Care

August 20th 2025

Huntsman Cancer Institute has announced leadership team appointments overseeing clinical and research efforts in theranostics.

FDA Approves MMR IHC Panel pharmDx as a Companion Diagnostic for Nivolumab/Ipilimumab in MSI-H/dMMR CRC

August 20th 2025

The FDA has approved the MMR IHC Panel pharmDx to determine eligibility for nivolumab/ipilimumab in patients with MSI-H/dMMR colorectal cancer.

Health Canada Approves Nivolumab Plus Ipilimumab for Unresectable MSI-H/dMMR CRC and Unresectable HCC

August 20th 2025

Nivolumab plus ipilimumab earned approval from Health Canada for select patients with unresectable colorectal cancer and hepatocellular carcinoma.

Novocure Files Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer

August 20th 2025

The FDA has received a premarket approval application supported by positive results from the PANOVA-3 trial for Tumor Treating Fields (TTFields)—electric fields that exert physical forces to kill cancer cells via a variety of mechanisms—for locally advanced pancreatic cancer.

Is It Time to Revisit How We Measure and Report the Toxicities of Antineoplastic Pharmaceutical Agents?

August 20th 2025

Maurie Markman, MD, discusses the need to reevaluate how adverse effects are measured and reported with antineoplastic therapies in oncology.

Oncology Conferences to Watch in the Second Half of 2025

August 20th 2025

Upcoming oncology meetings in the second half of 2025 will present new data across tumor types and offering updates that may influence standards of care.

Sasanlimab Plus BCG Emerges as a Potential Option for High-Risk NMIBC Despite Predictive Challenges

August 20th 2025

Thomas Powles, MD, MBBS, MRCP, discusses challenges in identifying a predictive biomarker of response for sasanlimab in high-risk, BCG-naive NMIBC.

FDA Issues CRL for SC Daratumumab Plus VRd for Transplant-Ineligible or -Deferred, Newly Diagnosed Multiple Myeloma

August 19th 2025

The FDA issued a complete response letter for subcutaneous daratumumab plus VRd in transplant-ineligible, newly diagnosed myeloma.

Chemo-Free Combination of Ribociclib/Trastuzumab/Letrozole Shows PFS Benefit in HR+/HER2+ Breast Cancer

August 19th 2025

Ribociclib plus trastuzumab and an AI produced a median PFS of 30.4 months in patients with hormone receptor–positive, HER2-positive breast cancer.

Fox Chase Cancer Center Researchers Discover ‘Cell-in-Cell’ Mechanism That Blood Cancer Uses to Evade Treatment

August 19th 2025

Fox Chase Cancer Center revealed for the first time that cancer cells can evade anti-cancer drugs by entering and surviving within bone marrow fibroblasts.

NCCN Adds Zongertinib to Clinical Practice Guidelines in NSCLC

August 19th 2025

The NCCN guidelines for NSCLC were updated to include zongertinib as a preferred subsequent therapy option for advanced or metastatic HER2-mutant NSCLC.